Elamipretide for Barth Syndrome: How It Works, What Trials Show, and FDA Status

Elamipretide is an investigational, mitochondria-targeted peptide that researchers have studied as a treatment for Barth syndrome, a rare X-linked disorder caused by abnormal cardiolipin and impaired mitochondrial energy production. In small clinical trials, some patients showed improvements in walking distance, muscle strength, and reported fatigue during open-label treatment. Elamipretide is not currently FDA-approved for Barth syndrome in the United States.

Because the disease is ultra-rare and treatment options are limited, families often search for "barth syndrome elamipretide" updates whenever new trial or regulatory news appears. This guide covers how the drug works, what the evidence shows, and what patients should ask their care team.

What Barth Syndrome Is

Barth syndrome is a rare genetic disorder that affects almost exclusively males. It is caused by mutations in the TAZ gene, which normally helps remodel cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane, where it supports the machinery that produces ATP.

When TAZ function is lost, cardiolipin composition becomes abnormal and mitochondria lose efficiency. The consequences typically include:

• Dilated cardiomyopathy, sometimes progressing to heart failure
• Neutropenia, which raises the risk of serious bacterial infections
• Skeletal myopathy and severe exercise intolerance
• Growth delay, feeding difficulties, and delayed puberty
• Lactic acidosis, hypoglycemia, and other metabolic abnormalities

Estimates place Barth syndrome at roughly 1 in 300,000 to 400,000 births, and there is no cure. Standard care focuses on heart failure medications, granulocyte colony-stimulating factor for neutropenia, nutrition support, and in severe cases, heart transplantation.

How Elamipretide Works

Elamipretide is a synthetic tetrapeptide, often written as D-Arg-Dmt-Lys-Phe-NH2. Its elamipretide structure — four amino acids, including an unusual dimethyltyrosine residue — makes it a small, cell-penetrating molecule that concentrates in the inner mitochondrial membrane rather than in the cytosol.

Once there, elamipretide binds cardiolipin, stabilizes cristae architecture, and helps the electron transport chain run more efficiently. Preclinical work also suggests it reduces reactive oxygen species that damage mitochondria under stress.

The rationale for pairing elamipretide with Barth syndrome is unusually direct: Barth syndrome is fundamentally a cardiolipin disease, and elamipretide is designed to protect cardiolipin. In research settings, elamipretide uses extend well beyond Barth syndrome, including studies in primary mitochondrial myopathy, heart failure, and age-related eye disease.

What the Clinical Trials Found

The most-cited elamipretide clinical trial in Barth syndrome is TAZPOWER, a Phase 2/3 study that combined a randomized, double-blind, placebo-controlled crossover phase with an open-label extension. It enrolled 12 participants with genetically confirmed Barth syndrome, a very small number that limits how firmly any result can be interpreted.

Reported outcomes were mixed. Some endpoints did not reach statistical significance during the blinded phase, while the open-label extension described improvements in six-minute walk distance, knee extensor strength, and patient-reported fatigue scores.

TAZPOWER enrolled only 12 patients, so its findings are best described as exploratory rather than definitive. Open-label results cannot separate drug effects from placebo response, natural variation, or the fact that patients feel better when they know they are being treated.

FDA Status and Patient Access

Elamipretide has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA. Those designations reflect the unmet need in Barth syndrome, but they do not equal approval.

Stealth BioTherapeutics submitted a New Drug Application for Barth syndrome, and the FDA responded with a Complete Response Letter in late 2024. The agency declined to approve the drug and asked for additional data, which typically means another adequate and well-controlled trial.

For families, the practical result is that no FDA-approved elamipretide product is available at U.S. pharmacies. Access currently happens through clinical trials, expanded access programs, or compassionate use arranged with the sponsor and a treating physician.

As of the FDA's most recent review, elamipretide is not approved for Barth syndrome, and additional clinical data will be required before approval can be reconsidered.

Dosing, Cost, and Practical Details

In TAZPOWER, elamipretide was given as a once-daily subcutaneous injection. The most commonly studied adult dose was 40 mg per day, and pediatric participants were dosed under protocol-specific regimens. Elamipretide is not an oral medication, and injection site reactions are common.

The elamipretide cost picture is not yet settled in the United States because there is no approved product. If approval comes, specialty therapies for ultra-rare diseases frequently carry list prices in the hundreds of thousands of dollars per year, and insurers often require prior authorization. Manufacturer support programs and patient foundation grants are usually the main financial pathways.

For anyone wondering about elamipretide pronunciation, it is commonly said "el-uh-MIP-ruh-tide."

Safety and What to Ask Your Doctor

In published trials, the most frequently reported side effects were injection site reactions such as redness, pain, and swelling, along with headache and mild gastrointestinal symptoms. Long-term safety data remain limited because so few patients have been treated.

Elamipretide is not a cure for Barth syndrome, and it should not be used outside a supervised trial or access program. Injectable peptides sold online as "research chemicals" are not the same product studied in trials, and their purity, sterility, and dosing are unverified.

Ask your care team specific questions: Is a clinical trial or expanded access program open to us? What monitoring does elamipretide require? What are the alternatives if we cannot get the drug? The Barth Syndrome Foundation and metabolic genetics clinics are reasonable starting points.

Anyone considering elamipretide for a child with Barth syndrome should talk with a cardiologist or metabolic specialist who knows the disease, because the unknowns of an investigational therapy must be weighed against the very real risks of cardiomyopathy and infection.